BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22237435)

  • 1. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
    Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
    Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
    Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
    Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.
    Kuehn HS; Caminha I; Niemela JE; Rao VK; Davis J; Fleisher TA; Oliveira JB
    J Immunol; 2011 May; 186(10):6035-43. PubMed ID: 21490157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
    Rieux-Laucat F; Magérus-Chatinet A; Neven B
    J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAS Haploinsufficiency Caused by Extracellular Missense Mutations Underlying Autoimmune Lymphoproliferative Syndrome.
    de Bielke MG; Perez L; Yancoski J; Oliveira JB; Danielian S
    J Clin Immunol; 2015 Nov; 35(8):769-76. PubMed ID: 26563159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic landscape of the FAS pathway deficiencies.
    Magerus A; Bercher-Brayer C; Rieux-Laucat F
    Biomed J; 2021 Aug; 44(4):388-399. PubMed ID: 34171534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next Generation Sequencing for Detecting Somatic
    López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
    Front Immunol; 2021; 12():656356. PubMed ID: 33995372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation.
    Hauck F; Magerus-Chatinet A; Vicca S; Rensing-Ehl A; Roesen-Wolff A; Roesler J; Rieux-Laucat F
    Clin Immunol; 2013 Apr; 147(1):61-68. PubMed ID: 23524443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults.
    Lambotte O; Neven B; Galicier L; Magerus-Chatinet A; Schleinitz N; Hermine O; Meyts I; Picard C; Godeau B; Fischer A; Rieux-Laucat F
    Haematologica; 2013 Mar; 98(3):389-92. PubMed ID: 22983577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
    Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
    Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
    Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
    Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
    Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
    J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
    Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
    Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
    Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
    Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations.
    Rieux-Laucat F; Blachère S; Danielan S; De Villartay JP; Oleastro M; Solary E; Bader-Meunier B; Arkwright P; Pondaré C; Bernaudin F; Chapel H; Nielsen S; Berrah M; Fischer A; Le Deist F
    Blood; 1999 Oct; 94(8):2575-82. PubMed ID: 10515860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats.
    Aberdein D; Munday JS; Gandolfi B; Dittmer KE; Malik R; Garrick DJ; Lyons LA;
    Mamm Genome; 2017 Feb; 28(1-2):47-55. PubMed ID: 27770190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
    Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
    Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.
    Siegel RM; Frederiksen JK; Zacharias DA; Chan FK; Johnson M; Lynch D; Tsien RY; Lenardo MJ
    Science; 2000 Jun; 288(5475):2354-7. PubMed ID: 10875918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene defects in the soma: some get it and some don't!
    Lo B; Lenardo MJ
    J Clin Invest; 2011 Jan; 121(1):16-9. PubMed ID: 21183786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.